
Dr Lee on the Mechanism of Action of Rina-S in FRα+ Platinum-Resistant Ovarian Cancer
"There’s a real need to try to expand [the use of] FRα-targeted therapies to more of our patients with ovarian cancer [who have differing levels of FRα expression]. Rina-S does carry a different payload than mirvetuximab soravtansine—exatecan, which …